← Back to browse
HR 1082 Passed a chamber

Requires the Health and Human Services Secretary to run an education effort on human cell and tissue product transplants, adds civil penalties for violations of federal rules on these products, and directs the Food and Drug Administration to publish data and seek recommendations for regulating them.

Official title: Shandra Eisenga Human Cell and Tissue Product Safety Act

Next stop Senate: awaiting action
Timeline each lane is a chamber; dates pull from congress.gov actions
House
Introduced 06-FEB-2025
Referred 06-FEB-2025
Approved by committee 29-APR-2025
Reported 12-JUN-2025
On the calendar 12-JUN-2025
Passed 23-JUN-2025
Senate
Received 24-JUN-2025
Key points
  • Requires the Secretary to support educational materials for health care professionals on organ, tissue, and eye donation and the availability of donor screening tests.
  • Sets civil penalties of up to $20,000 per violation, plus $20,000 per day for violations continuing after written notice, plus an amount equal to the products' retail value, with a $10,000,000 cap per proceeding.
  • Directs the FDA to publish Tissue Reference Group information and counts of facility registrations, inspections, and inquiries, with response times, within one year and annually for three years after.
  • Requires a public comment docket within 60 days and a report to Congress by September 30, 2026 with recommendations on regulating these products, weighing regulatory burden, scientific developments, access, and public health.
AI-generated from the Referred in Senate text of 24-JUN-2025 · verify · report an error
Official CRS summary

Covers an older version. The newest CRS summary describes the bill as of "Introduced in House" (06-FEB-2025); the text has changed since (Engrossed in House, 23-JUN-2025).

CRS is the Library of Congress's nonpartisan research office. Read it on congress.gov
Committee referrals (2) Policy area

Health

Sponsor John R. Moolenaar (R-MI) Cosponsors · 1
■ 1 D
1 Democrat